Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Spain's Almirall posts profit hike, ties outlook to coronavirus

Published 11/05/2020, 08:30
Updated 11/05/2020, 08:35

BARCELONA (Reuters) - Spain's Almirall (MC:ALM) on Monday said its first-quarter net profit rose 63% and it kept 2020 outlook steady, but said it may need to change it depending on how the novel coronavirus pandemic evolves.

Almirall's shares gained 5.8% by 7.06 GMT, outperforming Madrid's general index (SMSI), which was up 0.82%.

"In terms of the business, it is too early to estimate the long-term impact (of the coronavirus) on the health sector in general, and on Almirall in particular," the company's CEO Peter Guenter said in a statement.

"Nevertheless, we are satisfied with this first quarter, which has met the objectives set before the crisis."

The Barcelona-based pharmaceutical company reported net profit of 48.6 million euros ($52.67 million) between January and March versus 29.9 million euros in the same period in 2019 as revenue rose 7% and sales 8%, partly prompted by an increase in stockpiles related to the health crisis.

Almirall said it was maintaining for now its 2020 outlook of net sales growing in low to mid single-digit and adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) falling to between 260 million euros ($281.87 million) and 280 million euros from 304.2 million euros in 2019.

The dermatology specialist said the forecast was "subject to a normalisation of the health systems" at the end of the second quarter and the extent of the pandemic impact in the period, especially in the United States, given that prescriptions of its drugs declined after the virus outbreak there.

Almirall said its plants have continued to operate at full capacity despite lockdowns to control the coronavirus.

It said it had increased the production of paracetamol after verifying the drug could help ease the effects of COVID-19, the disease caused by the novel coronavirus.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.